Form 4 for CYTK CYTOKINETICS INC
Accepted 2021-11-02 00:00:00 ET · period of report 2021-11-01 · accession 0001061983-21-000247 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-02 | 2021-11-01 | CYTK | Cragg David | Chief HR, Admin Off | M - OptEx | $6.00 | +25.0K | 145.4K | +21% | +$150.0K |
| DM | 2021-11-02 | 2021-11-01 | CYTK | Cragg David | Chief HR, Admin Off | S - Sale+OE | $34.89 | -25.0K | 138.7K | -15% | -$872.2K |
| DM | 2021-11-02 | 2021-11-01 | CYTK | Cragg David | Chief HR, Admin Off | M - OptEx | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-01 | M | A | 18,325 | $6.00 | 157,029 | D | — | — | (F1) Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total. (F3) Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2021-11-01 | S | D | 6,675 | $34.89 | 138,704 | D | — | — | (F1) Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total. (F3) Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. |
| 3 | Common | Common Stock | 2021-11-01 | M | A | 6,675 | $6.00 | 145,379 | D | — | — | (F1) Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total. (F3) Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. |
| 4 | Common | Common Stock | 2021-11-01 | S | D | 18,325 | $34.89 | 138,704 | D | — | — | (F1) Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total. (F3) Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. |
| 5 | Derivative | Incentive Stock Option (right to buy) | 2021-11-01 | M | D | 18,325 | $0.00 | 0 | D | $6.00 · 2013-04-05 to 2023-03-05 | 18,325 Common Stock | |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-11-01 | M | D | 6,675 | $0.00 | 0 | D | $6.00 · 2013-04-05 to 2023-03-05 | 6,675 Common Stock |